 |
42 Diseases |  |
115 Trials |
|
115 Trials |  |
1644 News |  |
| «12...7891011121314151617...3031» |
- | pegylated liposomal doxorubicin / Generic mfg.
Journal: Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin. (Pubmed Central) - Dec 16, 2021
Our results along with prior studies indicate that the integration of exosome release inhibitors into the common PLD-containing chemotherapy regimens could significantly lower the required concentrations of the drug and consequently reduce its associated side effects. Further studies are warranted to identify clinically safe inhibitors and investigate their clinical efficacy.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Doxorubicin-sensitized Luminescence of NIR-emitting Ytterbium Liposomes: Towards Direct Monitoring of Drug Release. (Pubmed Central) - Dec 16, 2021
When doxorubicin and amphiphilic Yb 3+ chelates are incorporated into liposomes, the sensitized emission of Yb 3+ is dependent on the integrity of the particles which can be used to monitor drug release. We also established the first demonstration that the NIR Yb 3+ emission signal is observable in living mice following intratumoral injection of the Yb 3+ -doxorubicin-liposomes, using a commercial macroscopic setup equipped with a near-infrared camera.
- || tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Combination therapy: A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer (clinicaltrials.gov) - Dec 16, 2021
P1, N=80, Active, not recruiting, Sponsor: Hoffmann-La Roche
We also established the first demonstration that the NIR Yb 3+ emission signal is observable in living mice following intratumoral injection of the Yb 3+ -doxorubicin-liposomes, using a commercial macroscopic setup equipped with a near-infrared camera. Recruiting --> Active, not recruiting
- |||||||||| Duomeisu (pegylated liposomal doxorubicin) / CSPC Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial: Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer (clinicaltrials.gov) - Dec 15, 2021
P3, N=372, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- || dexamethasone / Generic mfg., pegylated liposomal doxorubicin / Generic mfg.
Clinical, Journal: Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients. (Pubmed Central) - Dec 15, 2021
Cooling patches can effectively reduce the frequency and severity of HFS caused by PLD in the short-term. In addition, it may help delay the decline in patients' self-efficacy.
- || pegylated liposomal doxorubicin / Generic mfg.
Clinical, Journal: Chemotherapy with a Pegylated Liposomal Doxorubicin-Containing Regimen in Newly Diagnosed Hodgkin Lymphoma Patients. (Pubmed Central) - Dec 2, 2021
All adverse events were grades 1-2. The PBVD regimen is an effective chemotherapy option with tolerable toxicity, and it could be a substitute in HL patients who cannot be treated with conventional doxorubicin, especially those with CVD or related risk factors.
- || AiRuiKa (camrelizumab) / Jiangsu Hengrui Medicine
Clinical, P2 data, Journal: Camrelizumab plus gemcitabine, vinorelbine and pegylated liposomal doxorubicin in relapsed/refractory primary mediastinal B-cell lymphoma: a single-arm, open-label, phase 2 trial. (Pubmed Central) - Nov 29, 2021
The PBVD regimen is an effective chemotherapy option with tolerable toxicity, and it could be a substitute in HL patients who cannot be treated with conventional doxorubicin, especially those with CVD or related risk factors. Camrelizumab plus GVD chemotherapy offers a potent option as life-saving chemo-immunotherapy with promising efficacy and a manageable safety profile for rrPMBCL patients, especially with bulky aggressive disease.
- || pegylated liposomal doxorubicin / Generic mfg., cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Trial completion date, Trial primary completion date: A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients (clinicaltrials.gov) - Nov 23, 2021
P2, N=254, Active, not recruiting, Sponsor: TTY Biopharm
Camrelizumab plus GVD chemotherapy offers a potent option as life-saving chemo-immunotherapy with promising efficacy and a manageable safety profile for rrPMBCL patients, especially with bulky aggressive disease. Trial completion date: May 2023 --> Oct 2022 | Trial primary completion date: Oct 2019 --> Oct 2022
- | Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion
Preclinical, Journal: Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma. (Pubmed Central) - Nov 21, 2021
In particular, the lower toxicity coupled with the higher anti-tumour activity on both the local treatment modalities strongly suggest a better therapeutic index when Myocet is administered through FBGs. Therefore, FBGs loaded with Myocet may be considered as a possible new tool for the loco-regional treatment of NB or even other tumour histotypes treatable by loco-regional chemotherapy.
- |||| pegylated liposomal doxorubicin / Generic mfg., Lynparza (olaparib) / Merck (MSD), AstraZeneca
Combination therapy: Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)☆ https://t.co/ApBmXbp5B6 (Twitter) - Nov 14, 2021
- | TH 1902 / Theratechnologies, TH-1904 / Theratechnologies
Biomarker, Journal, Tumor microenvironment: New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells. (Pubmed Central) - Nov 10, 2021
Overall, current data evidence for the first time that 1) SORT1 itself exerts a crucial role in both ES-2 and MDA-MB-231 VM, and that 2) VM in these cancer cell models can be efficiently inhibited by the peptide-drug conjugates TH1902/TH1904. These new findings also indicate that both peptide-drug conjugates, in addition to their reported cytotoxicity, could possibly inhibit VM in SORT1-positive TNBC and ovarian cancer patients.
- || pegylated liposomal doxorubicin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
P1/2 data, Journal, Combination therapy: A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer. (Pubmed Central) - Nov 7, 2021
P1/2
In this non-comparative study D-PLD demonstrated a higher activity than previously reported with single agent D with favorable side effect profile. A phase 3 study would be needed to evaluate the true benefit of this combination.ClinicalTrials.gov Identifier: NCT00456989.
- | pegylated liposomal doxorubicin / Generic mfg.
Preclinical, Journal: Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model. (Pubmed Central) - Nov 6, 2021
Our study indicated that the minibeam radiation therapy's ability to enhance the drug delivery decreases from 28 to 100 Gy peak dose. Our studies suggest that low-dose minibeam radiation therapy is a safe and effective method to significantly enhance the tumor delivery of nanoparticle agents.
- bortezomib / Generic mfg., pegylated liposomal doxorubicin / Generic mfg., decitabine / Generic mfg.
An Open-Label Phase II Trial of the Combination of Decitabine, SQ Bortezomib and Pegylated Liposomal Doxorubicin for the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3976;
DBP may serve as an effective bridge to BMT for some patients. This study supports further evaluation of DBP, or related combinations, in R/R AML.
- Kymriah (tisagenlecleucel-T) / Novartis
Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma (GWCC - Hall A1) - Nov 5, 2021 - Abstract #ASH2021ASH_1569;
P1
The majority of patients demonstrated a response per IPCG, including responses beyond 12 months. Tisagenlecleucel was found to expand in the peripheral blood and CNS with CSF gene signatures suggestive of higher CAR-T cell infiltrates in responding patients.
- || nibrozetone (RRx-001) / EpicentRx
Trial completion date, Trial primary completion date: RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) (clinicaltrials.gov) - Nov 3, 2021
P2, N=213, Active, not recruiting, Sponsor: EpicentRx, Inc.
Tisagenlecleucel was found to expand in the peripheral blood and CNS with CSF gene signatures suggestive of higher CAR-T cell infiltrates in responding patients. Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Dec 2021
- | siplizumab (TCD601) / ITBMed, Rituxan (rituximab) / Roche
Trial completion: Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas (clinicaltrials.gov) - Nov 3, 2021
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Dec 2021 Active, not recruiting --> Completed
- pegylated liposomal doxorubicin / Generic mfg.
DESENSITIZATION AND STEPPED REINTRODUCTION IN ANAPHYLAXIS TO PEGYLATED LIPOSOMAL DOXORUBICIN IN KAPOSI'S SARCOMA (Hall B (1st Floor); Monitor 02) - Nov 2, 2021 - Abstract #ACAAI2021ACAAI_722;
Subsequently, the PLD infusion was administered in a conventional manner every 3 weeks successfully. Discussion In our patient, the administration of PLD was essential due to the efficacy that has been demonstrated in the treatment of Kaposi's sarcoma, so the performance of desensitization provides a new horizon in the prognosis in patients with hypersensitivity reactions to drugs.
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Enrollment closed, Trial completion date, Trial primary completion date: Brentuximab for Newly Diagnosed Hodgkin Disease (clinicaltrials.gov) - Nov 2, 2021
P2, N=40, Active, not recruiting, Sponsor: Mitchell Cairo
Discussion In our patient, the administration of PLD was essential due to the efficacy that has been demonstrated in the treatment of Kaposi's sarcoma, so the performance of desensitization provides a new horizon in the prognosis in patients with hypersensitivity reactions to drugs. Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Jun 2021
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
[VIRTUAL] “A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer.” () - Nov 1, 2021 - Abstract #SWOGFall2021SWOG_Fall_383;
- || Lynparza (olaparib) / Merck (MSD), AstraZeneca
P2 data, Journal, Combination therapy, BRCA Biomarker, PARP Biomarker: Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). (Pubmed Central) - Oct 31, 2021
The PLD-olaparib combination has shown significant activity in PROC regardless of BRCA status. PLD at 30 mg/m is better tolerated in the combination.
- | pegylated liposomal doxorubicin / Generic mfg.
Preclinical, Journal: Observation of non-glandular gastritis associated with Doxil chemotherapy treatment in NSG™ mice. (Pubmed Central) - Oct 30, 2021
Of note, a study using a dose of 2 mg/kg Doxil was terminated early due to significant weight loss while the use of Doxil at 1 mg/kg allowed for repeated treatment of twice a week for a duration of three weeks. A dose optimised treatment regimen has now been established and can be applied to assess Doxil-related anti-tumour efficacy in a range of PDX-bearing NSG™ mice.
- || pegylated liposomal doxorubicin / Generic mfg.
PK/PD data, Preclinical, Journal: The pharmacokinetics of PEGylated liposomal doxorubicin are not significantly affected by sex in rats or humans, but may be affected by immune dysfunction. (Pubmed Central) - Oct 30, 2021
Further, reanalysis of published human data that formerly reported sex-differences in PLD plasma clearance similarly revealed no significant differences in PLD plasma clearance between males and females with solid tumours, but increased plasma clearance in patients with Kaposi's sarcoma (generally HIV+/immunocompromised). These data suggest that with the exception of lymphatic exposure, there are unlikely to be significant sex effects in the pharmacokinetics of liposomes, but immune function may contribute to inter individual variability.
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Review, Journal: Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches. (Pubmed Central) - Oct 30, 2021
Lipid and polymer-based drug-drug and drug-gene combinatorial nanocarriers delivering multiple chemotherapeutics simultaneously to desired site of action have been detailed. Finally, emerging opportunities such as pharmacological targets (immune check point and epigentic modulators) as well as gene-based modulation (siRNA/CRISPR/Cas9) and the nano-formulation challenges for effective treatment of both cancers have been explored.
- | pegylated liposomal doxorubicin / Generic mfg.
Journal: Acid-responsive HPMA copolymer-bradykinin conjugate enhances tumor-targeted delivery of nanomedicine. (Pubmed Central) - Oct 30, 2021
In addition, P-BK pre-treatment increased the tumor accumulation of pegylated liposomal doxorubicin (PLD) by approximately 3-fold...Collectively, P-BK pre-treatment improved intratumoral blood flow and augmented tumor accumulation of nanomedicine, thereby resulting in a significant suppression of tumor growth. Therefore, these findings demonstrate that P-BK is a potential concomitant drug for improving the tumor delivery of nanomedicines.
- || pegylated liposomal doxorubicin / Generic mfg., paclitaxel / Generic mfg.
Clinical, Retrospective data, Journal: The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials. (Pubmed Central) - Oct 28, 2021
In platinum-sensitive recurrent ovarian cancer, PLD plus carbo was more effective than PAC plus carbo, while in platinum-resistant or -refractory recurrent ovarian cancer, PLD exhibited similar survival to other monotherapies. Regarding side effects, PLD plus carbo and mono chemotherapy were both well tolerated.
- || pegylated liposomal doxorubicin / Generic mfg.
Clinical, Journal: Efficacy Of Pegylated Liposomal Doxorubicin-based Neoadjuvant Chemotherapy In Breast Cancer: A Single Center Experience. (Pubmed Central) - Oct 27, 2021
Higher histological grade was also associated high pCR rate (52.0% vs 40.0%). The use of PLD-containing chemotherapeutics in neoadjuvant settings might have benefits for non-metastatic operable breast cancer in Taiwanese females.
- ||| paclitaxel / Generic mfg.
Clinical, Journal, Adverse events: Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting. (Pubmed Central) - Oct 27, 2021
Existing trial data can be used to provide AE trajectories as illustrated here for ROC. These trajectories have utility in guiding treatment choice and potentially optimising AE management with novel therapies and treatment combinations.
- pegylated liposomal doxorubicin / Generic mfg.
Spatial, temporal and therapy dependent heterogeneity in transport phenotype of multiple liver metastases in murine breast cancer model (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_459;
Also, parental and selected two clonal cells exhibited different growth, response to PLD, and protein production in vitro . IVM imaging of individual liver metastasis over time using different cell lines revealed that relative fluorescent intensity of tracers transported inside/around tumor compared to that in the uninvolved tumor-free liver was more heterogeneous among parental cell derived tumors compared to clonal cells.
- |||||||||| nemvaleukin alfa (ALKS 4230) / Mural Oncology
New P3 trial, Combination therapy: Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (clinicaltrials.gov) - Oct 24, 2021
P3, N=376, Not yet recruiting, Sponsor: Alkermes, Inc.
- ||| Clinical, Next-generation sequencing: Thank you Dr. @JTrentMDPhD. Patient progressed on Gem-Docetaxel after 3 cycles. Pazopanib gave grade 3 diarrhea. Doxil also did not halt progression. Any benefit of trying lenvatinib in ur experience? Or any other drug that may help? NGS is pending. (Twitter) - Oct 22, 2021
- |||| pegylated liposomal doxorubicin / Generic mfg., Votrient (pazopanib) / Novartis
Next-generation sequencing: Any good ideas for extraskeletal osteosarcoma progressed after AIM-75 (response lasted 10 months), pazopanib, doxil, gem-tax? Has active Crohn's. NGS pend. ECOG 1 @JTrentMDPhD @jalivingston_md @bvantine1 @breelynwilkyMD @herbloong @NamBuiMD @RashmiChughMD @alegronchi @OncoAlert (Twitter) - Oct 22, 2021
- | Enrollment closed, IO biomarker: NRG-GY009: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Oct 18, 2021
P2/3, N=444, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
IVM imaging of individual liver metastasis over time using different cell lines revealed that relative fluorescent intensity of tracers transported inside/around tumor compared to that in the uninvolved tumor-free liver was more heterogeneous among parental cell derived tumors compared to clonal cells. Recruiting --> Active, not recruiting
- || doxorubicin hydrochloride / Generic mfg.
Clinical data, Preclinical, Journal: Injectable Drug Delivery Systems of Doxorubicin Revisited: In Vitro-In Vivo Relationships Using Human Clinical Data. (Pubmed Central) - Oct 14, 2021
The predictions required an estimation of the carrier half-life in blood circulation leading to considerable uncertainty. Still, the simulations narrow down the possible scenarios in the clinical evaluation of nanomedicines and provide a valuable addition to animal studies.
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) (clinicaltrials.gov) - Oct 13, 2021
P2, N=140, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Still, the simulations narrow down the possible scenarios in the clinical evaluation of nanomedicines and provide a valuable addition to animal studies. Not yet recruiting --> Recruiting
- pegylated liposomal doxorubicin / Generic mfg.
[VIRTUAL] FROM THE ENDOMETRIUM TO THE ATRIUM: A TREACHEROUS COURSE OF METASTASIS () - Oct 13, 2021 - Abstract #CHEST2021CHEST_926;
Treatment options include radiation therapy, chemotherapy with cisplatin followed by pegylated liposomal doxorubicin, and cryoablation of the mass. Cardiac involvement should be considered in patients presenting with dyspnea so that early targeted treatment may be initiated although its effects on outcomes need to be investigated.
- | pegylated liposomal doxorubicin / Generic mfg., vincristine / Generic mfg.
Journal: Synergistic co-loading of vincristine improved chemotherapeutic potential of Pegylated liposomal doxorubicin against triple negative breast cancer and non-small cell lung cancer. (Pubmed Central) - Oct 13, 2021
This carrier exhibited similar acute toxicity, pharmacokinetic and tissue distribution profiles with significant increase in tumor regression as compared to liposomal doxorubicin. These results indicate that co-encapsulation of vincristine into clinically used pegylated liposomal doxorubicin significantly improved in-vitro and in-vivo therapeutic efficacy against NSCLC and TNBC.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (clinicaltrials.gov) - Oct 12, 2021
P3, N=270, Recruiting, Sponsor: Advenchen Laboratories, LLC
These results indicate that co-encapsulation of vincristine into clinically used pegylated liposomal doxorubicin significantly improved in-vitro and in-vivo therapeutic efficacy against NSCLC and TNBC. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
- |||| Elahere (mirvetuximab soravtansine-gynx) / AbbVie
Trial completion, Combination therapy, Metastases: KEYNOTE PN409: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FR?) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Oct 12, 2021
P1b/2, N=264, Completed, Sponsor: ImmunoGen, Inc.
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024 Active, not recruiting --> Completed
- || etrumadenant (AB928) / Arcus Biosci, Gilead
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: ARC-2: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (clinicaltrials.gov) - Oct 11, 2021
P1, N=35, Completed, Sponsor: Arcus Biosciences, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=214 --> 35 | Trial completion date: Jul 2022 --> Jul 2021 | Trial primary completion date: Feb 2022 --> Jul 2021
- || Avastin (bevacizumab) / Roche
Clinical, Journal, Real-world evidence: Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients. (Pubmed Central) - Oct 8, 2021
P=N/A
Clinical outcomes and tolerability with bevacizumab in this real-life setting are consistent with randomized trial results, notwithstanding differences in the treated patient population and treatment schedule. Clinical Trial Registration:ClinicalTrials.gov, Identifier NCT01832415.
- || pegylated liposomal doxorubicin / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I-III Breast Cancer. (Pubmed Central) - Oct 8, 2021
Based on the large sample size and the long follow-up time of this study, we conclude that PLD has a similar anti-breast cancer efficacy as epirubicin while inducing lower level of cardiac toxicity in Han Chinese. This study suggests that PLD-based adjuvant chemotherapy could be a better option than epirubicin for breast cancer patients especially with existing cardiac disease.
- pegylated liposomal doxorubicin / Generic mfg.
Use of pegylated liposomal doxorubicin in patients with lymphoma and contraindications for anthracyclines () - Oct 7, 2021 - Abstract #DGHO2021DGHO_1066;
These patients represent a high-risk cohort associated with high mortality. Our results highlight CAD as less recognized risk factor for cardiotoxicity in patients with contraindications for anthracyclines.
- | pegylated liposomal doxorubicin / Generic mfg., lapatinib / Generic mfg.
Preclinical, Journal, Combination therapy: Development of a stable and high loaded liposomal formulation of lapatinib with enhanced therapeutic effects for breast cancer in combination with Caelyx®: In vitro and in vivo evaluations. (Pubmed Central) - Oct 7, 2021
Moreover, when it used in combination with liposomal doxorubicin, it extended the time to end from 22.4 ± 3.5 in the control group to 40 days in the TUBO cell line and from 29.2 ± 1.7 to 38.6 ± 2.2 days in 4T1 triple-negative breast cancer cell line, which reveals its promising effects on the survival of tumor-bearing mice. Our results indicated the need for further evaluations to understand liposomal lapatinib's potential effects on autophagy, apoptosis, and particularly on immune system cells.
- pegylated liposomal doxorubicin / Generic mfg.
[VIRTUAL] Neoadjuvant Acoustic Immune Priming With Low-Intensity Focused Ultrasound (LOFU) And Doxil For In Situ Tumor Vaccination In A Murine Triple-Negative Breast Cancer Model (Channel 3) - Oct 5, 2021 - Abstract #ACSCLINCON2021ACS_CLINCON_456;
Our results indicated the need for further evaluations to understand liposomal lapatinib's potential effects on autophagy, apoptosis, and particularly on immune system cells. Neoadjuvant acoustic immune priming of primary 4T1 tumors using LOFU and Doxil retained the survival benefit of chemotherapy but also yielded biologically significant immune activation of T cells in the TDLN, thereby acting as an in-situ tumor vaccine in a highly aggressive murine model of TNBC.
- ||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Clinical, P3 data, Journal, Combination therapy: Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). (Pubmed Central) - Oct 3, 2021
P3
It is planned to randomize 664 patients. NCT03353831.
- ATRC-101 / Atreca
Preclinical evaluation of pegylated liposomal Doxorubicin or Doxorubicin with mATRC-101 in the EMT6 syngeneic mouse model (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_472;
Exposure to Doxorubicin or PLD in EMT6 tumor-bearing mice increased mATRC-101 immunoreactivity in the tumor, in a dose-dependent manner Moreover, mATRC-101 immunoreactivity in normal tissues was not influenced by Doxorubicin or PLD. Taken together, these findings support clinical evaluation of the combination of ATRC-101 and doxorubicin.
- Avastin (bevacizumab) / Roche
Effectiveness of bevacizumab in platinum-resistant recurrent epithelial ovarian cancer () - Oct 1, 2021 - Abstract #ESGO2021ESGO_853;
Conclusion* bevacizumab had the predictable safety profile, with better effectiveness than the published in clinical trials, reflecting the small number of patients included in our real-world unicentric series. Nevertheless, new molecular biomarkers and clinical trials urge to improve outcomes in platinum-resistant recurrent ovarian cancer patients in clinical practice.
- Bavencio (avelumab) / EMD Serono, Pfizer
Avelumab alone in platinum-resistant/refractory ovarian cancer: selected biomarker analyses from the JAVELIN Ovarian 200 trial () - Oct 1, 2021 - Abstract #ESGO2021ESGO_752;
Multivariable analyses are ongoing. Conclusion* Although JAVELIN Ovarian 200 did not meet its primary endpoints, these analyses indicate potential subgroups of patients who could have improved outcomes with immunotherapy alone and provide insights into the biology of PRROC that may inform future trials.
- Avastin (bevacizumab) / Roche
Could change in neoadjuvant chemotherapy regimen after 3 cycles lead to better outcomes in inoperable ovarian cancer? () - Oct 1, 2021 - Abstract #ESGO2021ESGO_737;
Though the numbers in each group were small, a change to bevacizumab-based regimen did not appear to improve outcomes. The ICON 8b study will provide further information regarding bevacizumab's role in the neoadjuvant setting.